ATOS
NASDAQ
US
Atossa Therapeutics, Inc. - Common Stock
$5.37
▲ +$0.26
(+5.09%)
Vol 72K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$76.2M
ROE
-49.4%
Margin
-7412.5%
D/E
0.00
Beta
1.29
52W
$1–$1
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.94
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.94 | — | — |
| Dec 2025 | $-1.16 | $-3.08 | $-1.92 |
| Sep 2025 | $-1.02 | $-1.05 | $-0.03 |
| Jun 2025 | $-0.88 | $-1.05 | $-0.17 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$7.2M | -$6.3M | -$6.7M | -$8.4M | -$8.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -42.8% | -42.8% | -42.8% | -42.8% | -42.8% | -49.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -7412.5% | -7412.5% | -7412.5% | -7412.5% | -7412.5% |
| Gross Margin | — | 62.5% | 62.5% | 62.5% | 62.5% | 62.5% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.17 | 9.17 | 9.17 | 9.17 | 9.17 | 6.77 |
Key Ratios
ROA (TTM)
-44.8%
P/S (TTM)
476.32
P/B
1.7
EPS (TTM)
$-0.23
CF/Share
$-0.24
52W High
$1.29
52W Low
$0.55
$0.55
52-Week Range
$1.29
Financial Health
Free Cash Flow
-$6.0M
Cash
$51.8M
As of Sep 30, 2025
How does ATOS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ATOS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
476.3
▲
3607%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ATOS profitability vs Biotechnology peers
ROE
-49.4%
▲
27%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-7412.5%
▼
2485%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
62.5%
▼
20%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-44.8%
▲
4%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
ATOS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.8
▲
52%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
1.3
▲
33%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ATOS fundamentals radar
ATOS
Peer median
Industry
ATOS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ATOS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
QUAY STEVEN C
Chief Executive Officer · Jan 20
325203 shs
Last 90 days
Top Holders
Top 5: 11.9%Vanguard Group Inc
4.76%
$1.9M
Ameriprise Financial, Inc.
2.93%
$1.2M
Renaissance Technologies, L…
1.60%
$649K
Blackrock Inc.
1.55%
$629K
Geode Capital Management, L…
1.06%
$432K
As of Dec 31, 2025
Latest News
Kratos (KTOS) Slashes 8.8% as Middle East Tensions Dent Broader Market Further
Yahoo Finance · Mar 22
Kratos vs. Rocket Lab: Which Under-the-Radar Defense Stock Will Make You Richer?
Nasdaq · Mar 21
Why Kratos Defense Stock Popped, Then Dropped
Yahoo Finance · Mar 18
Is Kratos Defense & Security Solutions, Inc. (KTOS) The Best Drone Stock …
Yahoo Finance · Mar 17